CORESTEMCHEMON Inc. (KOSDAQ:166480)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,340.00
+20.00 (0.86%)
At close: Aug 28, 2025
0.86%
Market Cap57.00B
Revenue (ttm)24.83B
Net Income (ttm)-10.43B
Shares Out24.36M
EPS (ttm)-414.08
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume404,513
Average Volume356,797
Open2,320.00
Previous Close2,320.00
Day's Range2,290.00 - 2,520.00
52-Week Range2,000.00 - 15,610.00
Beta0.81
RSI39.99
Earnings DateAug 14, 2025

About CORESTEMCHEMON

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company has a strategic partnership ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2003
Employees 355
Stock Exchange KOSDAQ
Ticker Symbol 166480
Full Company Profile

Financial Performance

In 2024, CORESTEMCHEMON's revenue was 28.76 billion, a decrease of -14.54% compared to the previous year's 33.66 billion. Losses were -26.25 billion, 48.6% more than in 2023.

Financial Statements

News

There is no news available yet.